Interest of Oxytocin as an Adjuvant Treatment of Psycho-educational Measures in Challenging Behaviors in Children With Autism Spectrum Disorders and Moderate to Severe Intellectual Disability: Feasibility and Safety Study.

NCT ID: NCT05864508

Last Updated: 2023-05-18

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-07-31
• Study Completion Date: 2026-12-31

Brief Summary

The investigation team propose in this study to specifically evaluate the feasibility of using oxytocin in the form of an intranasal spray in a specific population of children with autism spectrum disorder and intellectual disability. The lack of studies centered on this population on the one hand, and on the other hand the severity of challenging behaviors presented by these children, make questionable the direct transfer of methods of care used in patients who do not present these challenging behavior. In this sense, the establishment of oxytocin treatment in these children requires a preliminary phase of feasibility assessment before being able to consider a comparative trial of the randomized clinical trial type.

Detailed Description

Taking into account:

• Intellectual disability comorbidity as a risk factor for challenging behaviors in the population with autism spectrum disorder;
• behavioral difficulties inherent in the presence of these behaviors, which are all potential obstacles to the administration of a treatment and therefore above all raise the question of the feasibility of administering such a treatment;
• the difficulty for children associating autism spectrum disorder of severe intensity and intellectual disability to benefit from clinical and paraclinical examinations given the concern generated by such examinations and challenging behaviors which can then occur in them, raising the question of feasibility monitoring protocol
• results of Oxytocin administration obtained in patients with autism spectrum disorder without associated intellectual disability;
• the favorable drug safety profile of oxytocin in children with autism spectrum disorder of the same age but without challenging behaviors;
• the extreme need for an effective treatment to control challenging behaviors in children with autism spectrum disorder with associated intellectual disability,

the investigation team propose in this study to specifically evaluate the feasibility of using oxytocin in the form of an intranasal spray in a specific population of children with autism spectrum disorder and intellectual disability. The lack of studies centered on this population on the one hand, and on the other hand the severity of challenging behaviors presented by these children, make questionable the direct transfer of methods of care used in patients who do not present these challenging behavior. In this sense, the establishment of oxytocin treatment in these children requires a preliminary phase of feasibility assessment before being able to consider a comparative trial of the randomized clinical trial type.

Conditions

Autism Spectrum Disorder

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

intranasal oxytocin

intranasal oxytocin treatment once a day during 6 weeks

Group Type: EXPERIMENTAL

Oxytocin nasal spray

Intervention Type: DRUG

intranasal oxytocin treatment once a day during 6 weeks

Interventions

Oxytocin nasal spray

intranasal oxytocin treatment once a day during 6 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Minor benefiting from a social security scheme.
• Diagnosis:autism spectrum disorder according to the Diagnostic and Statistical Manual DSM -5 of severe intensity;
• Comorbidities:
• Moderate to severe intellectual disability
• Presence of challenging behavior objectified by means of clinical examination and the ABC and ABC-I scales
• Multi-professional psycho-educational and re-educational care : global and coordinated interventions associating, according to the needs, educational interventions by targeted objectives, therapeutic interventions involving functions that do not develop spontaneously, adaptation of the environment by structuring time and space, in close collaboration with the families.
• If prescribed psychotropic treatments (antipsychotics, anxiolytics, hypnotics/sedatives, antidepressants, psychostimulants and antiepileptics), the dosages must be stable for 3 months*
• Understanding of French by both parents (if applicable) and ability for both parents to understand, in particular, the instructions for administering the product and to answer questionnaires.
• Informed consent signed by the holders of parental authority

Exclusion Criteria

• The refusal of the holders of parental authority
• Pregnant girls, determined by a positive baseline blood pregnancy test
• Criteria respecting the Syntocinon SPC:

• Hypersensitivity to Syntocinon
• Hyponatremia < 135 mmol/L
• Hypokalaemia < 3.5 mmol/L
• Hypertension or hypotension
• Behavioral intolerance to the intranasal route
• Hepatic impairment (ALT and/or AST > 3N)
• Kidney failure (creatinine > 3 N)
• History of an ECG considered to be clinically significant abnormal (validated by a cardiologist)
• Type 1 or 2 diabetes
• Prolongation of the QT interval and/or family history of QT prolongation linked to an identified genetic etiology (QTc prolongation threshold > 460 ms). **
• History of epilepsy or seizures
• Sexually active women of childbearing age without effective contraception*
• Breastfeeding women
• Severe cardiovascular disease (tachycardia, bradycardia, arrhythmias, hypertension, hypotension, myocardial ischemia)
• Latex allergy

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Toulouse

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Julie ANDANSON, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Toulouse

Locations

Toulouse University hospital

Toulouse, , France

Countries

France

Central Contacts

Julie ANDANSON, MD

Role: CONTACT

andanson.j@chu-toulouse.fr

05 61 77 80 75 ext. +33

Alexis REVET, MD, PhD

Role: CONTACT

revet.a@chu-toulouse.fr

Facility Contacts

Julie ANDANSON, MD

Role: primary

andanson.j@chu-toulouse.fr

Alexis REVET, MD, PHD

Role: backup

revet.a@chu-toulouse.fr

Other Identifiers

2022-000254-28

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

RC31/19/0500

Identifier Type: -

Identifier Source: org_study_id